LBA86 Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial

医学 恩扎鲁胺 前列腺癌 卡巴齐塔塞尔 生物标志物 肿瘤科 多西紫杉醇 危险系数 内科学 雄激素受体 临床终点 随机对照试验 紫杉烷 癌症 雄激素剥夺疗法 置信区间 乳腺癌 化学 生物化学
作者
Henrik Grönberg,Johan Lindberg,Bram De Laere,Alessio Crippa,Andrea Discacciati,Camilla Thellenberg Karlsson,Anders Ullén,Elin Jänes,Ashkan Mortezavi,Piet Ost,Gunilla Enblad,Jan Oldenburg,J. Sandzén,Linn Pettersson,M.N. Vigmostad,Marie Hjälm-Eriksson,Mats J. Olsson,Peter Schatteman,Christophe Ghysel,Martin Eklund
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1327-S1327
标识
DOI:10.1016/j.annonc.2023.10.088
摘要

The Prostate Biomarker (ProBio) trial is an international biomarker-driven, randomized, outcome-adaptive platform trial in men with metastatic castrate resistant prostate cancer (mCRPC) evaluating multiple agents. We used outcome-adaptive randomization to compare biomarker-driven treatment selection (experimental arms) against physician’s choice standard-of-care (SOC; control arm), and to compare agents against each other within the experimental treatment arms. Men with mCRPC were randomized based on genomic alterations in circulating tumor DNA in five biomarker signatures: (1) AR wt and TP53 wt; (2) TP53 mut; (3) DRD; (4) TMPRSS2:ERG fusion; (5) all biomarkers signatures combined. Androgen receptor pathway inhibitors (ARPi; abiraterone and enzalutamide) and taxanes (docetaxel and cabazitaxel) were evaluated, using progression-free survival, by no longer clinically benefiting per PCWG3 criteria (PFS), as primary endpoint. Enrollment in the experimental group was stopped when the Bayesian probability of superiority reached prespecified thresholds (“graduation”). In total, 219 men were randomized: 92 to SOC, vs. 76 and 51 to taxanes and ARPi, respectively, in the biomarker-driven arms. ARPi graduated in the “signature all”, i.e. a signature encompassing all biomarkers. The median estimated PFS was 11.3 months (90% Bayesian credible interval [CI], 9.8 to 13.1) for ARPi compared with 7.2 months (90% CI, 6.5 to 8.1) in the SOC arm, for a hazard ratio (HR) of 0.52 (90% CI 0.37 to 0.72). ARPi demonstrated superiority to taxanes within the experimental arms (HR 0.54; 90% CI 0.38 to 0.76). We observed suggestive differential treatment effects for patients with TP53 mut and TMPRSS2:ERG fusion disease. The median estimated overall survival (OS) was 37.3 months (CI, 27.7 to NA) for ARPi compared with 20.2 months (90% CI, 18.4 to 23.0) taxanes within the experimental arms. ARPi increases PFS and OS both compared to SOC and taxanes in patients with mCRPC. These are directly randomized data for ARPi and taxanes, showing the first evidence of a difference in PFS and OS for these agents in the mCRPC setting.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gsj完成签到,获得积分10
刚刚
1秒前
2秒前
秋天完成签到,获得积分10
3秒前
淡定的惜关注了科研通微信公众号
6秒前
Zhy发布了新的文献求助10
6秒前
7秒前
蛋挞完成签到,获得积分10
9秒前
李健应助Junning采纳,获得10
11秒前
11秒前
tingting9发布了新的文献求助10
12秒前
13秒前
爆米花应助mark采纳,获得10
14秒前
14秒前
爱看文献的小恐龙完成签到,获得积分10
15秒前
小饼干完成签到 ,获得积分10
17秒前
萧瑟处完成签到 ,获得积分10
18秒前
18秒前
19秒前
孙燕应助鹤鸣采纳,获得30
20秒前
21秒前
loski发布了新的文献求助10
23秒前
随便不放假完成签到 ,获得积分10
24秒前
淡定的惜发布了新的文献求助10
26秒前
威武的亦绿完成签到,获得积分10
26秒前
木丁完成签到,获得积分10
27秒前
27秒前
30秒前
量子星尘发布了新的文献求助30
32秒前
孙燕应助成就山河采纳,获得10
33秒前
34秒前
领导范儿应助幸福大白采纳,获得30
35秒前
谓风发布了新的文献求助10
35秒前
36秒前
q1356478314应助天白采纳,获得10
36秒前
Hanni完成签到 ,获得积分10
36秒前
37秒前
yixiaolou发布了新的文献求助10
37秒前
Junning发布了新的文献求助10
38秒前
39秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174